Sera Prognostics - IR Website

Home

News

Month Year

Investor Alerts

December 04

Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting

Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
December 02

Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
November 15

Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
November 06

SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
October 28

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
September 04

Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
August 08

Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
August 07

SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
July 25

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
July 09

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- Sera Prognostics...

Read More
July 01

SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 28

SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 08

SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
April 29

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 20

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 04

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 29

Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
December 06

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
November 22

SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
November 08

SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
October 25

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
September 21

SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
August 09

SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
July 31

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 25

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy...

Read More
May 15

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 10

SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
April 27

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 22

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 09

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 23

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 15

Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY, Feb. 15, 2023 /PRNewswire/ --

Read More
November 29

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

– Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce – SALT LAKE CITY and ARLINGTON, Va.,...

Read More
- Photos 1
November 15

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY, Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics...

Read More
November 09

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
October 27

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
October 04

SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif., Oct....

Read More
September 22

BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS

First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associated with preterm birth Salt Lake City and...

Read More
August 10

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
July 28

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
June 06

SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 19

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Sera...

Read More
May 18

SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING

SALT LAKE CITY, May 18, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
May 10

SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
May 05

SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT

Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
- Photos 2
May 02

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
April 12

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics...

Read More
- Photos 1
March 29

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 18

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
March 03

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 17

SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
February 07

SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
December 15

SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

Read More
December 02

SERA PROGNOSTICS ANNOUNCES PRICING FOR PRETRM® TEST, THE ONLY BROADLY VALIDATED BLOOD TEST TO ASSESS RISK OF PRETERM BIRTH

– New Assigned Rate Further Validates the Commercial Value of the PreTRM® Test –

Salt Lake City – Dec 2, 2021 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
December 01

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA CONFIRMING THE PERFORMANCE OF THE IBP4/SHBG BIOMARKERS IN DIVERSE NON-U.S. POPULATIONS

Results confirmed that a U.S. validated proteomics predictor could be applied in low and middle income countries to help address global preterm birth challenges

Salt Lake City, – December 1, 2021 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
November 30

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF SANDRA A. J. LAWRENCE TO THE SERA PROGNOSTICS BOARD

– Highly respected healthcare and financial leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies –

Salt Lake City, Nov. 30, 2021 (PR NEWSWIRE) — Sera PrognosticsInc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
November 09

SERA PROGNOSTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS

Salt Lake City – November 9, 2021 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
November 08

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF ZHENYA LINDGARDT TO ITS BOARD OF DIRECTORS

Noted healthcare and technology executive joins to help Sera achieve its vision as The Pregnancy Company® to improve maternal and newborn health

Salt Lake City, Nov. 8, 2021 (PR NEWSWIRE) — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
November 04

SERA PROGNOSTICS APPOINTS WOODROW MYERS, MD, MBA AS ADVISOR OF PUBLIC AND POLITICAL AFFAIRS

– Dr. Myers to support Sera’s commitment to reduce healthcare disparities among underserved communities –

Salt Lake City, Nov. 4, 2021 (PR NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
November 03

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF THE CLINICAL VALIDATION OF PreTRM® THRESHOLD FOR CLINICAL ACTION

Publication illustrates the power of stratifying PreTRM® testing risk at or above a threshold of twice the average population risk of spontaneous preterm birth (sPTB).

Salt Lake City – November 3, 2021 – Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
November 02

SERA PROGNOSTICS ANNOUNCES COLLABORATION TO HELP UNDERSERVED COMMUNITIES MAKE INFORMED DECISIONS ABOUT PRENATAL HEALTH

Partnership to include distribution of a children’s book with essential prenatal healthcare information and support in the form of pregnancy/NICU “care boxes”

Salt Lake City, Nov. 2, 2021 (PR NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
October 27

Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9

Salt Lake City, Oct. 27, 2021 (PR NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
September 28

SERA PROGNOSTICS APPOINTS DR. PAUL KEARNEY AS CHIEF DATA OFFICER

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

Salt Lake City, Sep. 28, 2021 (GLOBE NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...

Read More
September 15

SERA PROGNOSTICS APPOINTS DR. MICHAEL R. FOLEY AS CHIEF MEDICAL OFFICER

Salt Lake City, Sep. 15, 2021 (GLOBE NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...

Read More
September 14

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF HEALTH ECONOMIC ANALYSIS SUPPORTING PRETRM® TEST-AND-TREAT STRATEGY TO IMPROVE MATERNAL AND INFANT HEALTH

Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs

Salt Lake City – September 14, 2021 – Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information...

Read More
September 13

SERA PROGNOSTICS TO PRESENT AT OPPENHEIMER FALL HEALTHCARE LIFE SCIENCES & MED TECH SUMMIT

Salt Lake City – September 13, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
August 30

SERA PROGNOSTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS

Salt Lake City – August 30, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
August 17

Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility

Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

SALT LAKE CITY, Aug. 17, 2021 (GLOBE NEWSWIRE) — Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
July 14

Sera Prognostics Announces Pricing of Initial Public Offering

Salt Lake City – July 14, 2021 – Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
May 19

Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth

– The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
May 18

EVALUATION OF HEALTH AND ECONOMIC BENEFIT OF THE PRETRM® TEST-AND-TREAT STRATEGY TO IMPROVE MATERNAL AND INFANT HEALTH AMONG COMMERCIALLY INSURED IN THE US

– Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings

Salt Lake City – May 18, 2021 – Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to...

Read More
April 28

Sera Prognostics Completes $100 Million Series E Financing

– Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test –

SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative...

Read More
April 13

Sera Prognostics Appoints Benjamin G. Jackson as General Counsel

– Highly accomplished attorney joins Sera to develop its legal and intellectual property functions –

SALT LAKE CITY, April 13, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
March 31

SERA PROGNOSTICS APPOINTS ROBERT G. HARRISON AS CHIEF INFORMATION OFFICER

– Accomplished technology leader joins Sera to build and deploy its information strategy –

Salt Lake City – March 31, 2021 – Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to...

Read More
February 15

SERA PROGNOSTICS TO PRESENT AT THE BTIG VIRTUAL MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE

February 15, 2021 — Sera Prognostics, Inc., a leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at...

Read More
February 03

AMERICAN MEDICAL ASSOCIATION (AMA) GRANTS SERA PROGNOSTICS A CPT® PLA CODE FOR PreTRM®, THE ONLY BROADLY VALIDATED BLOOD TEST TO ASSESS RISK OF PRETERM BIRTH

– Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test –

Salt Lake City – February 3, 2021 – Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches,...

Read More
January 05

Sera Prognostics Partners With Anthem and HealthCore to Improve Outcomes for Preterm Babies

– Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care-

SALT LAKE CITY, January 5, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker...

Read More

Show per page

Email Alerts